1 / 33

Redesign of an Intraosseous Needle

University of Pittsburgh Senior Design – BioE 1160/1161. Redesign of an Intraosseous Needle. Jonathan Hughes Michael Audette Christopher Sullivan April 18, 2006 Mentor: James Menegazzi, Ph.D. The Intraosseous Needle. Intraosseous (IO) needle Access to venous system via IO pathway

royal
Télécharger la présentation

Redesign of an Intraosseous Needle

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. University of Pittsburgh Senior Design – BioE 1160/1161 Redesign of an Intraosseous Needle Jonathan Hughes Michael Audette Christopher Sullivan April 18, 2006 Mentor: James Menegazzi, Ph.D.

  2. The Intraosseous Needle • Intraosseous (IO) needle • Access to venous system via IO pathway • Components • Needle (14-16 gauge) • Trocar • Plastic housing • Insertion Technique • Placed through cortex • Fluid delivery to marrow • Driven by hand, spring, • or drill action Cook Critical Care, Inc. 2000

  3. IO Access • Major IO Infusion Sites • Pediatric • Proximal tibia (1-5 yrs.) • Adult • Sternum • Tibia (proximal or distal) • Alternate sites • Iliac crest • Distal shaft of the femur Jamshidi IO needle

  4. Proximal Tibia Infusion http://www.vitaid.com

  5. IO Applications • Emergency medicine • Limited access to venous system • Severe burns, trauma, hypovolemic shock, etc. • Fluid and pharmacological resuscitation • Bolus infusion (rapid delivery) • Continuous infusion • Supplemental therapy • Marrow sampling • Clinical settings

  6. Problem Statement • Problem: • Insertion technique and location may result in IO needle occlusion • Requires reinsertion • 15 gauge IO needle redesign: • Facilitate infusion by providing alternate flow paths • Addition of distal side ports • Maintain mechanical strength of needle Occluded IO Insertion

  7. Competitive Analysis • Competitors • Manual insertion • Cook • Jamshidi • Mechanical insertion • EZ-IO (VidaCare) • Bone Injection Gun (WaisMed) • Strengths • Allows the provider to continue to deliver drugs in the event of needle end occlusion • The manual needle, which is our focus, can be used multiple times while spring-loaded devices (i.e., Bone Injection Gun) can only be used once • Weaknesses • With the use of the automatic injection devices, occlusion is not a major problem, although it still happens (~2%)

  8. FDA Regulation Code of Federal Regulations TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES PART 880 – GENERAL HOSPITAL AND PERSONAL USE DEVICES Subpart F--General Hospital and Personal Use Therapeutic Devices • Sec. 880.5570 Hypodermic single lumen needle. • (a) Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set. • (b) Classification.Class II (performance standards). US Food and Drug Administration: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=880.5570

  9. Project Goals • Redesign a manual 15 gauge intraosseous needle that will allow for continued flow in case of needle tip occlusion (through the addition of distal sideports) • Specific goals • Maintain mechanical stability of the IO needle - CosmosWorks and In vitro testing • If properly inserted, our IO needle should have the same functionality as current IO needles • Capable of delivering 200 cc/min of fluids • If not properly inserted (tip occlusion), our IO needle should still allow for the delivery of meds through the sideports • This additional functionality is not present in current IO needles • Minimize extravasation • Sideports cannot be too far distal - lead to extravasation during occluded infusion • Sideports cannot be too proximal - lead to extravasation during normal infusion

  10. Basic Project Timeline

  11. Design Selection Tree How many sideports to add and where? 3+ sets of sideports, 2+ setsof long sideports Addition of Sideports One set of sideports Two sets of sideports Circular Elongated Inline Offset Model A Model C Model B Model D

  12. FEA Testing • Finite Element Analysis testing was done in Solidworks and Floworks • Scenarios to model: • Normal infusion • Occluded infusion (simulated with ideal wall at tip) • Compare models to each other without the need for costly prototype iterations • Allowed for design parameters to easily be changed and retested

  13. Normal Infusion Cut Plot Locations In-hole Flow Trajectories • In normal infusion, ~99% of the flow leaves through the tip (essentially no flow through sideports) • Therefore, during normal infusion, our needle designs function the same as current IO needles Velocity Profile Cutplot (red = higher v) 75 velocity flow trajectories, none leave through the sideports

  14. Occluded Functionality – One sideport – Model A Velocity Profile Cutplot (red = higher v) 75 flow trajectories (velocity) • Heavy backflow (15-20% of overall flow) • High flow velocities out of sideports – could possibly result in hemolysis • Models B and D have more desirable flow patterns • Eliminated

  15. Model A Flow Trajectory Video

  16. Occluded – One sideport – Model C Velocity Profile Cutplots (red = higher v) 75 flow trajectories (velocity) • Light backflow • Flow profile is similar to Models B and D • Eliminated because Models B and D yield similar results, but are cheaper to manufacture

  17. Occluded – Two sideports – Model B Velocity Profile Cutplots (red = higher v) 75 flow trajectories (velocity) • Light backflow (2-3%) • ~60% of flow out of distal sideport, ~40% out of proximal sideport • Essentially all flow has left the needle by the end of the most distal sideport • Prototyped

  18. Model B Flow Trajectory Video

  19. Occluded – Two sideports – Model D Velocity Profile Cutplots (red = higher v) 75 flow trajectories (velocity) • Light backflow (2-3%) • Very similar flow profile to Model B • Essentially all flow has left the needle by the end of the most distal sideport • Could be prototyped and compared to Model B (future work)

  20. Model D Flow Trajectory Video

  21. Prototype • Two prototypes of Model B were produced • Manufactured by Vitaneedle out of 316 Stainless Steel • 316 Stainless steel is the material used in current needles • A Luer Lock hub was attached to the proximal end • The device was modeled to make use of the current Jamshidi needle holder for testing purposes since PIM was not feasible

  22. Constraints limiting testing • Our trocar did not fit properly into the lumen of the needle prototype • Modification of the trocar without compromising tip occlusion was not possible • As a result, direct insertion of our prototype into bone was not feasible • To compensate, a pilot hole using a current needle was first drilled and then our needle was inserted • Our planned in vitro mechanical stability testing was not possible • However, our trocarless hollow needle was hammered into bone to model total tip occlusion and showed no mechanical deformation when removed

  23. Experimental Methods • Flow Rate Determination • Time (in seconds) elapsed to infuse 200 mL of 0.9% saline solution was measured • Steady pressure drop of 275 mm Hg to 300 mm Hg maintained by a pressure infusion bag • Five cases: • Current Jamshidi IO needle (no sideports) without occlusion • Current Jamshidi IO needle with occlusion • Redesigned IO needle without occlusion • Redesigned IO needle with occlusion from rubber stopcock • Redesigned IO needle with simulated occlusion in distal end of porcine tibia bone cortex • 10 Trials of each case

  24. In-Vitro Testing

  25. In-Vitro Testing II

  26. In-Vitro Testing III

  27. Results

  28. Discussion of Results • Over 10 trials, our redesigned IO needle was able to deliver ~300 cc/min of fluid in the event of both cases of tip occlusion • Very similar to non-occluded cases • 300 cc/min more than adequately satisfies our baseline goal of 200 cc/min • Therefore, there appeared to be virtually no difference in infusion time of 200 mL of fluid • Obviously, when the tip is occluded in the current IO needle (without sideports), flow is blocked, and there is no path for infusion • In the case of the non-occluded needle with sideports, we noticed that all flow passed through the open end even with the sideport openings • Minimal Extravasation

  29. Testing (con’t) • Dr. Menegazzi used our prototype in testing a deceased porcine test subject • The result was that there happened to be needle tip occlusion inadvertently, but aspiration still took place • This shows that the sideports provided an alternate path for fluid flow

  30. Human Factors • Device does not require the device user population to be highly skilled in needle operation techniques • Training with device will consist of the formal training that is standard to normal intraosseous needle use • Familiarization of users with the slight differences between the new design and current products of which the users already have experience using • Device will be used in the field in emergency care and thus may be used in any location • Hospitals • Stationary and or Moving Vehicles (i.e., ambulances)

  31. Member Responsibilities

  32. Acknowledgements • James Menegazzi, PhD • Steven Abramowitch, PhD • VitaNeedle • University of Pittsburgh Department of Bioengineering • Generous donation from Drs. Hal Wrigley & Linda Baker • Mark Gartner

  33. Questions ???

More Related